The cardiac marker point-of-care (POC) market is expected to rise across the 15 major markets of the US, Canada, Mexico, France, Germany, Italy, Spain, Russia, the UK, Japan, China, India, South Korea, Australia, and Brazil, from around $311 million in 2016 to almost $398 million by 2023, representing a compound annual growth rate of 3.6%, according to research and conscoulting firm GlobalData.
The company’s latest report states that key drivers in this market include the rising prevalence of cardiovascular disease, increasing use of troponin POC testing (POCT) in pre-hospital settings such as ambulances, improved sensitivity of cardiac market POCT, and increasing uptake of cardiac market POCT in primary care.
Nadia McLurcan, GlobalData’s Analyst covering Medical Devices, explains: “The adoption of cardiac market POC tests such as troponin enables patients with acute coronary syndrome to arrive at hospital with results from a biomarker test. As a result, the patient can be triaged much faster and put on an appropriate treatment plan.”
POCT in ambulances is available in some European countries but has not yet been widely adopted in the US. One potential issue is the reliability of testing in a moving ambulance, although evidence from one study suggests that troponin test results are not affected. GlobalData predicts the uptake of POCT in ambulances will continue to be a driver of market growth in Europe, but does not expect significant adoption in the US over the forecast period.
McLurcan continues: “Despite the steady market rise, there will be a number of significant barriers to growth over the forecast period. For example, thorough management of POCT can be demanding. Testing may involve multiple devices or kits and many operators who have to be managed in order to assure quality. Indeed, larger facilities with numerous devices and locations often employ dedicated POC co-ordinators to ensure the proper usage of POC equipment.
“An additional obstacle with POCT is in changing the ways of working for numerous medical professionals. The method has repeatedly been referred to as a ‘disruptive technology,’ as it requires a change from the traditional paradigm of testing being completed by a lab technician. In many emergency departments, nurses and doctors will be expected to carry out POC testing themselves, which has been a significant barrier in some hospitals.”
About GlobalData
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information
Contact the GlobalData press office +44 (0)161 359 5822
or
email pr@globaldata.com.
